<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sophia Genetics Sa — News on 6ix</title>
<link>https://6ix.com/company/sophia-genetics-sa</link>
<description>Latest news and press releases for Sophia Genetics Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sophia-genetics-sa" rel="self" type="application/rss+xml" />
<item>
<title>SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-to-announce-financial-results-for-first-quarter-2026-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-to-announce-financial-results-for-first-quarter-2026-on-may-5-2026</guid>
<pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
<description>SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.</description>
</item>
<item>
<title>Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/mount-sinai-health-system-and-sophia-genetics-announce-collaboration-to-advance-precision-cancer-care-from-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/mount-sinai-health-system-and-sophia-genetics-announce-collaboration-to-advance-precision-cancer-care-from-aacr-2026</guid>
<pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
<description>SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities.</description>
</item>
<item>
<title>SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-reports-fourth-quarter-and-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-reports-fourth-quarter-and-full-year-2025-results</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported</description>
</item>
<item>
<title>SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-to-present-at-the-46th-annual-td-cowen-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-to-present-at-the-46th-annual-td-cowen-health-care-conference</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced</description>
</item>
<item>
<title>SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-to-announce-financial-results-for-fourth-quarter-and-full-year-2025-on-march-3-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-to-announce-financial-results-for-fourth-quarter-and-full-year-2025-on-march-3-2026</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.</description>
</item>
<item>
<title>SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-announces-major-expansion-142200450</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-announces-major-expansion-142200450</guid>
<pubDate>Tue, 10 Feb 2026 14:22:00 GMT</pubDate>
<description>SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.</description>
</item>
<item>
<title>SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-provides-preliminary-fourth-120000840</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-provides-preliminary-fourth-120000840</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman.</description>
</item>
<item>
<title>SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-md-anderson-announce-130000172</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-md-anderson-announce-130000172</guid>
<pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
<description>SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.</description>
</item>
<item>
<title>SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-complete-genomics-integrate-140000295</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-complete-genomics-integrate-140000295</guid>
<pubDate>Tue, 11 Nov 2025 14:00:00 GMT</pubDate>
<description>Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made f</description>
</item>
<item>
<title>SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-element-biosciences-unite-130100714</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-element-biosciences-unite-130100714</guid>
<pubDate>Tue, 11 Nov 2025 13:01:00 GMT</pubDate>
<description>SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine.</description>
</item>
<item>
<title>Complete Genomics and SOPHiA GENETICS Announce Integration of MSK-IMPACT® and MSK-ACCESS® Assays on DNBSEQ-T1+ Platform at AMP 2025</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/complete-genomics-and-sophia-genetics-announce-integration-of-msk-impactr-and-msk-accessr-assays-on-dnbseq-t1-platform-at-amp-2025</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/complete-genomics-and-sophia-genetics-announce-integration-of-msk-impactr-and-msk-accessr-assays-on-dnbseq-t1-platform-at-amp-2025</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS</description>
</item>
<item>
<title>SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-reports-third-quarter-114500244</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-reports-third-quarter-114500244</guid>
<pubDate>Tue, 04 Nov 2025 11:45:00 GMT</pubDate>
<description>SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-announce-financial-results-120000513</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-announce-financial-results-120000513</guid>
<pubDate>Tue, 21 Oct 2025 12:00:00 GMT</pubDate>
<description>SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.</description>
</item>
<item>
<title>SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-launches-ai-powered-080100317</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-launches-ai-powered-080100317</guid>
<pubDate>Thu, 16 Oct 2025 08:01:00 GMT</pubDate>
<description>SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions.</description>
</item>
<item>
<title>A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/adam-innovations-and-sophia-genetics-partner-to-advance-liquid-biopsy-testing-and-companion-diagnostics-for-precision-oncology-in-japan</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/adam-innovations-and-sophia-genetics-partner-to-advance-liquid-biopsy-testing-and-companion-diagnostics-for-precision-oncology-in-japan</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS</description>
</item>
<item>
<title>Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/myriad-genetics-and-sophia-genetics-to-develop-an-innovative-companion-diagnostic-offering-in-liquid-biopsy</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/myriad-genetics-and-sophia-genetics-to-develop-an-innovative-companion-diagnostic-offering-in-liquid-biopsy</guid>
<pubDate>Tue, 23 Sep 2025 04:00:00 GMT</pubDate>
<description>SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and</description>
</item>
<item>
<title>Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/myriad-genetics-and-sophia-genetics-to-develop-an-innovative-companion-diagnostic-offering-in-liquid-biopsy-1</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/myriad-genetics-and-sophia-genetics-to-develop-an-innovative-companion-diagnostic-offering-in-liquid-biopsy-1</guid>
<pubDate>Tue, 23 Sep 2025 04:00:00 GMT</pubDate>
<description>SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine,</description>
</item>
<item>
<title>SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-expands-collaboration-astrazeneca-120000915</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-expands-collaboration-astrazeneca-120000915</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS's AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.</description>
</item>
<item>
<title>SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of Pathology</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-jessa-ziekenhuis-announce-080000726</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-jessa-ziekenhuis-announce-080000726</guid>
<pubDate>Fri, 05 Sep 2025 08:00:00 GMT</pubDate>
<description>SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has announced a significant new collaboration with Jessa Ziekenhuis in Hasselt, Belgium. The institutions will partner to bring cutting edge genomic testing and oncology research to cancer patients across Belgium.</description>
</item>
<item>
<title>SOPHiA GENETICS Reports Second Quarter 2025 Results</title>
<link>https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-reports-second-quarter-104500605</link>
<guid isPermaLink="true">https://6ix.com/company/sophia-genetics-sa/news/sophia-genetics-reports-second-quarter-104500605</guid>
<pubDate>Tue, 05 Aug 2025 10:45:00 GMT</pubDate>
<description>SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025.</description>
</item>
</channel>
</rss>